Challenging Cases to CNS Current Approaches
Each member of the multi-disciplinary panel will present a current controversy in the management of CNS tumors including diffuse gliomas, glioblastoma, re-irradiation, interpreting imaging changes following novel therapies, and brain metastases as well as provide input on their interpretation of available data relevant to the clinical scenario and describe how this data impacts their clinical practice. The faculty will provide a consensus correct answer with supporting data from the recent published literature..
This program is designed to meet the interest of radiation oncologists, pathologists, radiation biologists and residents-in-training.
- Recognize the substantial heterogeneity that exists within these tumor types and understand the prognostic and predictive variables that allow for the selection of the appropriate therapy
- Discuss recent literature supporting the role of radiation therapy in the multidisciplinary management of CNS tumors
- Discuss key imaging modalities and features to differentiate recurrent tumor and treatment effect and to identify brain tumor micmics
The following people served as the developers of this activity and their disclosures are listed below.
- Daniel Cahill, MD, PhD, is employed by the Mass General Physicians Organization and receives compensation from Merck
- Patrick Wen, MD, is employed at Dana-Farber Cancer Institute and receives compensation from Genentech/Roche, Novartis, Regeneron,Vascular Biogenics, Monteris, Cavion, Merck, Agios, Angiochem, Astra Zeneca.
- Christina Tsien, MD, is employed at the Washington University at St. Louis and holds a leadership position with RSNA Oncologic Imaging Committee.
- Meng Law, MD, is employed at USC and receives compensation from Guerbet, Bracco Diagnostics, Toshiba, Samsung, Prism Clinical Imaging, holds ownership or investment interests in Prism Clinical imaging and leadership positions in ASSR and ASFNR.
Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.